Menorrhagia Clinical Trials

Find Menorrhagia Clinical Trials Near You

A Pre-Market, Pivotal, Interventional, Clinical Investigation to Evaluate the Performance and the Safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) in Premenopausal Women With Abnormal Uterine Bleeding (AUB)

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Abnormal uterine bleeding (AUB) is defined as flow outside of normal volume, duration, regularity, or frequency. Acute AUB is excessive bleeding that requires immediate intervention to prevent further blood loss. Chronic AUB refers to irregularities in menstrual bleeding for most of the previous 6 months. AUB can be frequent or infrequent, prolonged, irregular, or heavy. Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional and/or material quality of life. Causes of AUB are classified as polyps, adenomyosis, leiomyomas (AUB-L), malignancy and premalignant conditions, coagulopathy, ovulatory disorders (AUB-O), endometrial disorders (AUB-E), iatrogenic, and 'not classified ' . AUB affects approximately one in four women between 30 and 50 years of age, with serious implications on woman's quality of life (QoL). Endometrial ablation (EA) is a uterus-preserving procedure that aims to destroy or remove the endometrial tissue in selected women who have no desire for future fertility. EA has become an alternative to hysterectomy in the treatment of AUB because it is less invasive and has a shorter recovery period. At present, many different techniques are available to remove the endometrial tissue. Resectoscopic endometrial ablation (REA) consists of targeted endometrial destruction under direct hysteroscopic visualization. REA techniques include endometrial laser ablation, transcervical resection of the endometrium, and rollerball endometrial ablation. Non-resectoscopic endometrial ablation (NREA) uses a variety of energy sources to non-selectively destroy the endometrial lining and include thermal balloon endometrial ablation, microwave endometrial ablation, hydrothermal ablation, bipolar radiofrequency endometrial ablation, endometrial cryotherapy, and more recently vapor endometrial ablation. NREA technologies require short surgical time and can also be performed in the outpatient setting. Vapor EA is one of the newest approaches in the field. In this context, the Aqua Therapeutics Thermal Therapy Vapor Ablation system (ATTTVAS; AQUA Therapeutics Inc.) is a novel system designed to ablate uterine tissue using vapor thermal therapy technology. The ATTTVAS is indicated to ablate the endometrial lining of the uterus in premenopausal women with abnormal uterine bleeding (AUB) due to benign causes for whom childbearing is complete. In this A Pre-Market, Pivotal, Interventional, Clinical Investigation to Evaluate the Performance and the Safety of the Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) in premenopausal women with Abnormal Uterine Bleeding (AUB)

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 30
Maximum Age: 55
Healthy Volunteers: f
View:

⁃ Patients will be eligible if, at screening (V-1), they will meet all of the following inclusion criteria except having a PBAC score ≥150 since this score can only be calculated at baseline visit (V0).

• Signed patient informed consent form (ICF).

• Females aged ≥ 30 years and ≤ 55 years at baseline with no desire to conceive, with or without simple endometrial hyperplasia (without atypia).

• Diagnosis of AUB.

• Premenopausal (follicle-stimulating hormone level ≤ 40 mIU/mL), women who don't want to receive hormonal treatment or who have failed to respond to hormonal treatment.

• Pictorial Blood Loss Assessment Chart (PBAC) score ≥150 at baseline.

• Normal endometrial biopsy.

• Negative PAP test.

• Willingness to follow all study procedures, including attending all site visits, tests, and examinations. NOTE: diagnosis of AUB will include AUB history, current menstrual condition (collected at screening visit), physical examination (performed at screening and at baseline visit), blood test results (from blood samples collected at screening visit) and will be confirmed by a PBAC score ≥150 (at baseline visit).

Locations
Other Locations
Georgia
LTD High Technology Hospital Medcenter
RECRUITING
Batumi
LTD Gagua Clinic
RECRUITING
Tbilisi
LTD Todua Clinic
RECRUITING
Tbilisi
Contact Information
Primary
Tinatin Gagua, MD
info@gaguaclinic.ge
+99532 2 122 122
Time Frame
Start Date: 2025-04-08
Estimated Completion Date: 2027-03-31
Participants
Target number of participants: 43
Treatments
Experimental: Treatment with Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) medical device
All Patients shall be screened for initial study eligibility by the Principal Investigator at the investigational site. Potential candidates, that according to the investigator judgment should be treated with IP, will be identified, with the assessment of their eligibility criteria, by the study site Principal Investigator and research staff. Patients will be considered to be enrolled in the study once they have met all of the inclusion and none of the exclusion criteria. Patients who do not meet the criteria will not be enrolled in the study. The patient involvement in the study will last until the EOS visit.
Sponsors
Leads: Aqua Therapeutics, Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials